AR102

Schistosomiasis affects more than 185 million people worldwide, with the vast majority of cases occurring in Africa. Current treatment relies largely on praziquantel, which is effective against adult worms but has limited activity against immature parasite stages and does not prevent reinfection. To address this important unmet need, the project will advance AR102, DNDi’s lead pre-clinical candidate for schistosomiasis and a promising next-generation potential treatment that has demonstrated activity against both juvenile and adult worms.

Through a comprehensive package of pre-clinical development activities, including process development and scale-up, regulatory safety studies, formulation development, and translational pharmacokinetic/pharmacodynamic (PK/PD) modelling, the project will generate the evidence required to support a decision on readiness for first-in-human clinical studies. By strengthening the pipeline of novel schistosomiasis treatments, this work aims to accelerate the development of safe, affordable field-adapted therapies that can act across multiple parasite life stages.